Previous 10 | Next 10 |
Altadena, CA, July 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . ( Nasdaq: LIXT ) (“Lixte” or the “Company”) noted that Julio Pimentel, a fourth-year doctoral student in the Wayne State University School of Medicine’s Cancer ...
Presentation to highlight Company’s current clinical stud y of lead compound LB-100 for Small Cell Lung Cancer ALTADENA, CA, July 07, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: LIXT) (“Lixte” or the “...
Lixte Biotechnology Holdings ([[LIXT]] -0.7%) announces the enrollment of the first patient in a Phase 1b clinical trial to assess the combination of LB-100 with a standard regimen for previously untreated, extensive stage-disease small cell lung cancer ((ED-SCLC)).The trial for LB-...
Extensive preclinical data shows LB-100 increases the effectiveness of chemotherapy in animal models Due to the aggressive progression of small cell lung cancer, it is possible that therapeutic benefit in patients may ...
Lixte Biotechnology Holdings (LIXT) +21%.LightPath Technologies (LPTH) +16%.Reata Pharmaceuticals (RETA) +14% as FDA requested pre-NDA meeting for Omaveloxolone.Verona Pharma (VRNA) +10%.Cerecor (CERC) +6%.TAT Technologies (TATT) +5% on partnership with Lufthansa Technik Shenzhen ...
May 19 - 20, 2021 Presentation times and weblinks released for over 60 presenting companies NEW YORK, NY / ACCESSWIRE / May 18, 2021 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day spring Microcap Virtual Conference taking place Wedne...
Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical p...
EAST SETAUKET, NY, May 12, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. ( Nasdaq : LIXT ) today announced the appointment of Regina Brown, CPA to its board of directors. She will serve as an independent director and audit committee chair. Dr. John S. Kov...
Multiple pre-clinical studies indicate that Lixte’s lead clinical drug candidate LB-100 enhances the effectiveness of many standard anticancer treatments EAST SETAUKET, NY, May 04, 2021 (GLOBE NEWSWIRE) -- ...
Lixte’s pipeline includes three clinical studies and one pharmacology study of lead drug candidate LB-100 EAST SETAUKET, NY, April 28, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: LIXT), a clinical-stage drug disc...
News, Short Squeeze, Breakout and More Instantly...
Lixte Biotechnology Holdings Inc. Company Name:
LIXT Stock Symbol:
OTCMKTS Market:
Lixte Biotechnology Holdings Inc. Website:
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ...
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ȁ...
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( ...